The effectiveness of intermittent isotretinoin treatment in mild or moderate acne

Journal of the European Academy of Dermatology and Venereology

Volumn 20, Issue 10, 2006, Pages 1256-1260

  Kaymak, Yesim ^a,b,c   Illter, N ^a,b  

^a GAZI UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

^c NONE   (Turkey)

Author keywords

Acne vulgaris; Intermittent treatment; Isotretinoin; Low dose therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; ISOTRETINOIN; TRIACYLGLYCEROL;

ACNE; ADULT; ARTHRALGIA; ARTICLE; CHEILITIS; CLINICAL FEATURE; CONJUNCTIVITIS; CONTROLLED STUDY; DERMATITIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG RESPONSE; DRUG SAFETY; DRY SKIN; EPISTAXIS; FATIGUE; FEMALE; HEADACHE; HEALING; HUMAN; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MYALGIA; NERVOUSNESS; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME;

ACNE VULGARIS; ADOLESCENT; ADULT; DERMATOLOGIC AGENTS; FEMALE; HUMANS; ISOTRETINOIN; MALE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33750320907     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2006.01784.x     Document Type: Article

References (28)

1. Dreno B, Poli F. Epidemiology of acne. Dermatology 2003; 43: 1042-1048.
2. Strauss JS, Thibautat DM. Diseases of the sebaceous glands. In: Freedberg I, Eisen AZ, Wolff K et al., eds. Dermatology in General Medicine, 5th edn. McGraw-Hill, New York, 1999: 769-784.
3. Cunliffe WJ, van de Kerkhof PCM, Caputo R et al. Roaccutane treatment guidelines: Results of an international survey. Dermatology 1997; 194: 351-357.
4. Peck GL, Olsen TG, Batkus D et al. Isotretinoin versus placebo in the treatment of cystic acne. A randomized double-blind study. J Am Acad Dermatol 1982; 6: 735-745.
5. Goulden V, Clark SM, Mcgeown C, Cunliffe WJ. Treatment of acne with intermittent isotretinoin. Br J Dermatol 1997; 137: 106-108.
6. Burke BM, Cunliffe WJ. The assessment of acne vulgaris - the Leeds technique. Br J Dermatol 1984; 111: 83-92.
7. Ellis CN, Krach KJ. Uses and complications of isotretinoin therapy. J Am Acad Dermatol 2001; 45: 150-157.
8. Leyden JJ, McGinley KJ, Foglia AN. Qualitative and quantitative changes in cutaneous bacteria associated with systemic isotretinoin therapy for acne conglobata. J Invest Dermatol 1986; 86: 390-393.
9. Coates P, Adams CA, Cunliffe WJ et al. Does oral isotretinoin prevent Propionibacterium acnes resistance? Dermatology 1997; 195: 4-9.
10. Eady EA, Jones CE, Tipper JL, Cove JH, Cunliffe WJ, Layton AM. Antibiotic resistant propionibacteria in acne: Need for policies to modify antibiotic usage. Br Med J 1993; 306: 555-556.
11. Layton AM, Knaggs H, Taylor J, Cunliffe WJ. Isotretinoin for acne vulgaris -10 years later: A safe and successful treatment. Br J Dermatol 1993; 129: 292-296.
12. Layton AM, Cunliffe WJ. Guidelines for optimal use of isotretinoin in acne. J Am Acad Dermatol 27: S2-S7.
13. Goulden V, Layton AM, Cunliffe WJ. Current indications for isotretinoin as a treatment for acne vulgaris. Dermatology 1995; 190: 284-287.
14. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998; 139: 846-850.
15. Kellet SC, Gawkodger DJ. The psychological and emotional impact of acne and the effect of treatment with isotretinoin. Br J Dermatol 1999; 140: 273-282.
16. Aktan S, Ozmen E, Sanli B. Anxiety, depression and nature of acne vulgaris in adolescents. Int J Dermatol 2000; 39: 354-357.
17. Mallon E, Newton JN, Klassen A, Ryan TJ, Finlay A. Standard patient-assessed quality of life instruments can be used to measure the benefits of acne treatment. Br J Dermatol 1995; 133: 45-35.
18. Chivot M, Midoun H. Isotretinoin and acne: A study of relapses. Dermatologica 1990; 180: 240-243.
19. Stainforth JM, Layton AM, Taylor JP, Cunliffe WJ. Isotretinoin for the treatment of acne vulgaris: Which factors may predict the need for more than one course? Br J Dermatol 1993; 129: 297-301.
20. Piquero-Martin J, Misticone S, Piquero-Casals V, Piquero-Casals J. Topic therapy-mini isotretinoin doses vs. topic therapy-systemic antibiotics in the moderate acne patients. Ann Dermatol Venereol 2002; 129: 382.
21. Marks R. Acne and its management beyond the age of 35 years. Am J Clin Dermatol 2004; 5: 459-462.
22. Plewig G, Dressel H, Pfleger M, Michelsen S, Kligman A. Low dose isotretinoin combined with tretinoin is effective to correct abnormalities of acne. JDDG 2004; 2: 31-45.
23. Seukeran DC, Cunliffe WJ. Acne vulgaris in the elderly: The response to low-dose isotretinoin. Br J Dermatol 1998; 139: 99-101.
24. Palmer RA, Sidhu S, Goodwin PG. 'Microdose'isotretinoin. Br J Dermatol 2000; 143: 205-206.
25. Amichai B. Long-term mini-doses of isotretinoin in the treatment of relapsing acne. J Dermatol 2003; 30: 572.
26. Zoubolis CC, Piquero-Martin J. Update and future of systemic acne treatment. Dermatology 2003; 206: 37-53.
27. Strauss JS, Leyden JJ, Lucky AW et al. A randomized trial of the efficacy of a new micronized formulation versus a standard formulation of isotretinoin in patients with severe recalcitrant nodular acne. J Am Acad Dermatol 2001; 45: 187-195.
28. Mandekov-Lefaki I, Delli F, Teknetzis A, Euthimiadov R, Karakatsanis G. Low-dose schema of isotretinoin in acne vulgaris. Int J Clin Pharmacol Res 2003; 23: 41-46.